Given the large number of genes alternatively spliced in high-risk neuroblastoma patients [23], we next sought to investigate the changes in the splicing landscape resulting from disruptions to MYCN and SNRPD3 expression. The gene discussed is MYCN; the disease is neuroblastoma.